The Metabolism and Biopharmaceutics of Spironolactone in Man

Drug Metabolism and Drug Interactions

Volumn 5, Issue 4, 1987, Pages 273-302

  Overdiek, Hans W P M ^a   Merkus, Frans W H M ^b  

^a Clinical Pharmacokinetics and Toxicology Laboratory Hospital of Sittard ^*  (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANRENONE; SPIRONOLACTONE;

ADULT; AGED; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; FEMALE; GYNECOMASTIA; HUMAN; HUMAN EXPERIMENT; HYPERALDOSTERONISM; MALE; NORMAL HUMAN; NORMAL VALUE; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; REVIEW;

AGED; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; HUMAN; SPIRONOLACTONE;

EID: 0023512031     PISSN: 07925077     EISSN: 21910162     Source Type: Journal    
DOI: 10.1515/DMDI.1987.5.4.273     Document Type: Article

References (115)

1. Ings, R.M.J., and Stevens, L.A. Pharmacokinetics and metabolism of diuretics. In: Bridges, J.W. and Chasseaud, L.F., eds, Progress in Drug Metabolism, Volume 7. Chichester: John Wiley and Sons, 1983; 129–45.
2. Karim, A., Kook, C., Zitzewitz, DJ., Zagarella, J., Doherty, M. and Campion, J. Species differences in the metabolism and disposition of spironolactone. Drug Metab. Dispos. 1976;: 547–555.
3. Gochman, N. and Gantt, C.L. A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma. J. Pharmacol. Exp. Ther. 1962; 135: 312–316.
4. Sadee, W., Dagcioglu, M. and Schroder, R. Pharmacokinetics of Aldactone in humans. In: Brendel, W., Coraboeuf, E., Ebling, FJ.G. et al, eds, Extrarenal activity of Aldosterone and its antagonists. Amsterdam: Excerpta Medica 1972; 40–42.
5. Ramsay, L., Asbury, M., Shelton, J. and Harrison I. Spironolactone and canrenoate-K: Relative potency at steady-state. Clin. Pharmacol. Ther. 1977; 21: 602–609.
6. Gerhards, E. and Engelhardt, R. Zum Stoffwechsel von 3-(3-Oxo-7α acetyl - thio - 7β- hydroxy 4 -androsten -17α-yl)-propionsaure-γ-lacton. Arzneim. Forsch. 1963; 13: 972–977.
7. Zicha, L., Weist, F., Scheiffarth, F., and Schmid, E. Dünnschicht-chromatographische Untersuchungen des 3-(3-Oxo-7α-acetylthio-l 7β-hydroxy-4-androsten-17α-yl)-propionsäure-γ-lactons und seiner Meta-boliten beim Menschen. Arzneim. Forsch. 1964; 14: 699–705.
8. Wayner, H., Weist, F. and Zicha, L. Aldadien und andere Metaboliten im Blut und Ham nach rectaler Applikation von Spironolacton und intravenoser Injektion von Aldadien-Kalium. Arzneim Forsch. 1967; 17: 415–419.
9. Karim, A. and Brown, E.A. Isolation and identification of novel sulfur-containing metabolites of spironolactone (Aldactone). Steroids 1972; 20:41-62.
10. Karim, A., Hribar, J., Aksamit, W., Doherty, M., and Chinn, LJ. Spironolactone metabolism in man studied by gas chromatography-mass spectrometry. Drug Metab. Dispos. 1975; 3: 467–478.
11. Karim, A., Zagarella, J., Hribary, J. and Dooley, M. Spironolactone. I. Disposition and metabolism. Gin. Pharmacol. Ther. 1975; 19: 158–169.
12. Abshagen, U. and Rennekamp, H. Isolation and identification of a sulfur-containing metabolite of spironolactone from human urine. Steroids 1976; 28: 467–480.
13. Abshagen, U., Rennekamp, H. and Luszpinski, G. Pharmacokinetics of spironolactone in man. Naunyn-Schmied. Arch. Pharmacol. 1976; 296: 37-45.
14. Karim, H., Hribar, J., Doherty, M., Aksamit, W., Chappelow, D., Brown, E., Markos, C., Chinn, LJ., Liang, D. and Zagarella, J. Spironolactone: diversity in metabolic pathways. Xenobiotica 1977; 7: 585–600.
15. Sadee, W., Abshagen, U., Finn, C. and Rietbrock, N. Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats. Naunyn-Schmied. Arch. Pharmacol. 1974; 283: 303–318.
16. Karim, A., Ranney, R.E. and Maibach, HJ. Pharmacokinetic and metabolic fate of potassium canrenoate (SC-14266) in man. J. Pharm. Sci. 1971; 60: 708–715.
17. Garrett, E.R. and Won, C.M. Prediction of stability in pharmaceutical preparations XVI: Kinetics of hydrolysis of canrenone and lactonization of canrenoic acid. J. Pharm. Sci. 1971; 60: 1801–1809.
18. Sadee, W., Dagcioglu, M. and Schroder, R. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J. Pharmacol. Exp. Ther. 1973; 185: 686–695.
19. Sadee, W., Finn, A.M., Schmiedek, P. and Baethmann, A. Aldosterone plasma radioimmunoassay interference by a spirolactone metabolite. Steroids 1975; 25: 301–311.
20. Weissenborn, U. and Erbler, H.C. Metabolism of spirolactones by the rat testis in vitro. Steroids 1983;42: 365–388.
21. Koch, R.L., Hauswald, C.L. and Oppermann, J.A. Pharmacokinetics and metabolism of canrenone and canrenoic acid after an oral dose of potassium canrenoate or spironolactone in the rat. Pharmacologist 1984; 26: 167.
22. Vose, C.W., Boreham, D.R., Ford, G.C., Haskins, NJ. and Palmer, R.F. Identification of some human urinary metabolites of orally administered potassium canrcnoate by stable-isotope labelling techniques. Drug Metab. Dispos. 1979; 7: 226–32.
23. Sherry, J.H., O'Donnell, J.P. and Colby, H.D. Conversion of spironolactone to an active metabolite in target tissues: Formation of 7a-thiospironolactone by microsomal preparations from guinea pig liver, adrenals, kidneys, and testes. Life Sci. 1981; 29: 2727–2736.
24. Sherry, J.H., O'Donnell, J.P., Flowers, L., Lacagnin, L.B. and Colby, H.D. Metabolism of spironolactone by adrenocortical and hepatic microsomes: Relationship to cytochrome P450 destruction. J.Pharmacol. Exp. Ther. 1986; 236: 675-680.
25. Erbler, H.C. Effect of spironolactone and its main metabolite canrenone on the renin-angiotensin-aldosterone-system during long-term treatment in rats. Acta Endocrinol. 1979; 90: 147–156.
26. Keith, R.A., Jardine, I., Kerremans, A. and Weinshilboum, R.M. Human erythrocyte membrane thiol methyltransferase. S-Methylation of captopril, N-acetyl-cysteine, and 7α-thio-spirolactone. Drug Metab. Dispos. 1984; 12: 717–724.
27. Sadee, W., Dagcioglu, M. and Riegelman, S. Fluorimetric microassay for spironolactone and its metabolites in biological fluids. J. Pharm. Sci. 1972; 61: 1126–1128.
28. Neubert, P. and Koch, K. Simultaneous automated determination of spironolactone metabolites in serum. J. Pharm. Sci. 1977; 66: 1131–1134.
29. Dahlof, C.G., Lundborg, P., Persson, B.A. and Regardh, C.G. Re-evaluation of the anti-mineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method. Drug Metab. Dispos. 1979; 7: 103–107.
30. Neurath, G.B. and Ambrosius, D. High-performance liquid chromatographic determination of canrenone, a major metabolite of spironolactone, in body fluids. J. Chromatogr. 1979; 163; 230-255.
31. Abshagen, U., Besenfelder, E., Endele, R., Koch, K. and Neubert, B. Kinetics of canrenone after single and multiple doses of spironolactone. Eur. J. Clin. Pharmacol. 1979; 16: 255–262.
32. Besenfelder, E. and Endele, R. High performance liquid chromatographic method for determination of canrenone in serum. J. High Resolut. Chromatogr. Commun. 1981; 4: 419-421.
33. Stuber, W., Mutschler, E. and Steinbach, D. Zur Spezifitat der Bestimmung von Canrenon in biologischen Flüssigkeiten. Arch. Pharm. 1981; 314: 148–156.
34. Merkus, F.W.H.M., Overdiek, J.W.P.M., Cilissen, J. and Zuidema, J. Pharmacokinetics of spironolactone after a single dose: Evaluation of the true canrenone serum concentrations during 24 hours. Clin. Exp. Hypertens. 1983; A5: 239–248.
35. Krause, W., Karras, J. and Seifert, W. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-Kin healthy man. Eur. J. Clin. Pharmacol. 1983; 25: 449–453.
36. Overdiek, J.W.P.M., Cilissen, J., Hermens, W.AJJ. and Merkus, F.W.H.M. The importance of canrenone in the metabolism of spironolactone. Pharm. Weekbl. Sci. Ed. 1984; 6: 270.
37. Ho, P.C., Bourne, D.W.A., Triggs, E.J. and Heazlewood, V. Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone. Eur. J. Clin. Pharmacol. 1984; 27: 441–446.
38. Kojima, K., Yamamoto, K., Fujioka, H. and Kaneko, H. Pharmacokinetics of spironolactone and potassium canrenoate in humans. J. Pharmacobio-Dyn. 1985; 8: 161–166.
39. Chamberlain, J. Gas chromatographic determination of levels of aldadiene in human plasma and urine following therapeutic doses of spironolactone. J. Chromatogr. 1971; 55: 249–253.
40. Feher, T., Bodrogi, L. and Varadi, A. Simple gas chromatographic method with flame ionization detection for the determination of aldadiene in human urine. J. Chromatogr. 1976; 123: 460–462.
41. Overdiek, J.W.P.M., Hermens, W.A.J.J. and Merkus, F.W.H.M. Determination of the serum concentration of spironolactone and its metabolites by high-performance liquid chromatography. J. Chromatogr. 1985; 341: 279–285.
42. Von Vergin, H., Nuss, U., Schwarzländer, F., Strobel, K., Weigand, W. and Hitzenberger, G. Bioverfügbarkeitsuntersuchung zweier Spironolacton-Praparate. Arzneim. Forsch. 1981; 31: 1498–1503.
43. Overdiek, J.W.P.M., Hermens, W.AJJ. and Merkus, F.W.H.M. New insights into the pharmacokinetics of spironolactone. Clin. Pharmacol. Ther. 1985; 38: 469–474.
44. Sponer, G., Kaufmann, B. and Kuhr, M. Pharmakokinetik von Aldosteron-Antagonisten. Krankenhausarzt 1976; 49: 569–575.
45. Ramsay, L., Shelton, J., Harrison, I., Tidd,M. and Asbury, M. Spironolactone and potassium canrenoate in normal man. Clin. Pharmacol. Ther. 1976; 20: 167–177.
46. Jackson, L., Branch, R., Levine, D. and Ramsay, L. Elimination of canrenone in congestive heart failure and chronic liver disease. Eur. J. Clin. Pharmacol. 1977; 11: 177–179.
47. Karim, A. Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metab. Rev. 1978; 8: 151–188.
48. Von Vergin, H., Nuss, U. and Strobel, K. Untersuchungen zur Pharmakokinetik und Bioverfügbarkeit von Bendroflumethiazid in Kombination mit Spironolacton. Arzneim. Forsch. 1986; 36: 490–495.
49. Abshagen, U., Von Grodzicki, U., Hirschberger, U. and Rennekamp, H. Effect of enterohepatic circulation on the pharmacokinetics of spironolactone in man. Naunyn-Schmied. Arch. Pharmacol. 1977; 300: 281–287.
50. Sadee, W., Schroder, R., Von Leitner, E. and Dagcioglu, M. Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure. Eur. J. Clin. Pharmacol. 1974; 7: 195–200.
51. Abshagen, U., Rennekamp, H. and Luszpinski, G. Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment. Eur. J. Clin. Pharmacol. 1977; 11: 169–176.
52. Varadi, A., Feher, T., Bodrogi, L. and Koref, O. Spironolactone metabolism in normal subjects and in patients with liver cirrhosis. Arzneim. Forsch. 1977; 27: 1617–1620.
53. Overdiek, J.W.P.M. and Merkus, F.W.H.M. Spironolactone metabolism and gynaecomastia. Lancet 1986; 1: 1103.
54. Abshagen, U., Platt, D. and Horn, HJ. Zur Pharmakokinetik von Spironolacton im Alter. Klin. Wochenschr. 1981; 59: 909–910.
55. Platt, D., Abshagen, U., Mühlberg, W., Horn, HJ., Schmitt-Ruth, R. and Vollmar, J. The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone. Arch. Gerontol Geriatr. 1984; 3: 147–159.
56. Ho, P.C., Bourne, D.W.A., Triggs, E J. and Smithurst, B.A. Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone. Eur. J. Clin. Pharmacol. 1984; 27: 435–439.
57. Gantt, C.L., Gochman, N. and Dyniewicz, J.M. Effect of a detergent on gastrointestinal absorption of a steroid. Lancet 1986; 1: 486–487.
58. Gantt, C.L., Gochman, N. and Dyniewicz, J.M. Gastrointestinal absorption of spironolactone. Lancet 1962; 1: 1130–1131.
59. Noel, P.R. and Leahy, J.S. The estimation of the activity of aldosterone antagonist in man: spironolactone (Aldactone) activity. Clin. Sci. 1962; 23: 477–483.
60. Kagawa, C.M., Bouska, DJ. and Anderson, M.L. Oral absorption with various preparations of spironolactone in dogs. J. Pharm. Sci. 1964; 53: 450–451.
61. Bauer, G., Rieckmann, P. and Schaumann, W. Einfluss von Teilchengrosse und Losungsvermittlern auf die Resorption von Spironolacton aus dem Magen-Darmtrakt. Arzneim. Forsch. 1962; 12: 487–489.
62. D'Athis, P., Richard, M.O., De Lauture, D., Rey, E., Bouvier d’Yvoire, M., Clement, E. and Olive, G. Etude comparative des disponibilites de deux formes de spironolactone. Therapie 1981; 36: 443–449.
63. Portal, A., Gaillot, J., Bieder, A., Rodary, C. and Bertharion, J J. Des aspects de la biodisponibilite physiologique de la spironolactone et de la canrenone. Sem. Hôp. 1976; 5: 465–470.
64. Mclnnes, G.T., Asbury, MJ., Ramsay, L.E., Shelton, J.R. and Harrison, I.R. Effect of micronization on the bioavailability and Pharmacologic activity of spironolactone. J. Clin. Pharmacol. 1982; 22: 410–417.
65. Levy, G. Availability of spironolactone given by mouth. Lancet 1962; 2: 723–724.
66. Clarke, J.M., Ramsay, L.E., Shelton, J.R., Tidd, M.J., Murray, S. and Palmer, R.F. Factors influencing comparative bioavailability of spironolactone tablets. J. Pharm. Sci. 1977; 66: 1429–1432.
67. Tidd, K.J., Collins, W.I. and Chamberlain, J. A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites. J. Int. Med. Res. 1976; 4: 86–95.
68. Raptis, G., Wendt, H., Meister, R. and Fuchs, P. In vitro and in vivo availability of spironolactone from various oral preparations. Drug. Dev. Ind. Pharm. 1978; 4: 389–411.
69. Chao, A.Y., Sanvordeker, D.R., Zagarella, J., Mattes, K., Nicholova, B. and Karim, A. In vitro and in vivo availability of spironolactone from oral dosage forms. J. Pharm. Sci. 1976; 65: 1630–1634.
70. Karim, A., Zagarella, J., Hutsell, T.C., Chao, A.Y. and Baltes, BJ. Spironolactone, II. Bioavailability. Clin. Pharmacol. Ther. 1976; 19: 170–176.
71. Hofmann, L.M., Dutt, J.E., Deysach, L.G., Loncin, H. and Tao, L. Comparison of spironolactone tablet dosage forms in healthy humans. J. Pharm. Sci. 1974; 63: 1248–1253.
72. Von Erking, W., Lücker, P.W., Stocker, K.P. and Wetzelsberger, K. Relative bioverfügbarkeit einer neuen Spironolacton-Zubereitung. Arzneim. Forsch. 1979;29: 1184–1189.
73. Von Rosenthal, J., Jaeger, H. and Specker, M. Vergleichende Untersuchung der relativen Bioverfügbarkeit mehrerer Spironolacton-Zubereitungen im Steady-state-Versuch. Arzneim. Forsch. 1979; 29: 1428–1432.
74. Rameis, H., Hitzenberger, G. and Horwatitsch, H. The bioavailability of a spironolactone hydrochlorothiazide combination preparation. Int. J. Clin. Pharmacol. Ther. Toxicol. 1982; 20: 327–333.
75. Nijkerk, A.J., Vermeer, J.M., Imanse, M. and De Vos, D. The bioavailability of two new preparations of spironolactone tablets. Pharm. Weekbl. Sci. Ed. 1983; 5: 210–212.
76. Melander, A., Danielson, K. Schersten, B., Thulin, T. and Wahlin, E. Enhancement by food of canrenone bioavailability from spironolactone. Clin. Pharmacol. Ther. 1977; 22: 100–103.
77. Overdiek, J.W.P.M. and Merkus, F.W.H.M. Influence of food on the bioavailability of spironolactone. Clin. Pharmacol. Ther. 1986; 40: 531–536.
78. Mulgaard Anderson, F. and Bundgaard, H. Inclusion complexation of spironolactone with cyclodextrins. Arch. Pharm. Chem. Sci. Ed. 1983; 11: 7–14.
79. Debrueres, B., Bretillon, A. and Duchêne, D. Improvement of solubility and bioavailability of spironolactone by inclusion in β-cyclodextrin. Proc. Int. Symp. Control Rel. Bioact. Mater. 1985; 12: 118–119.
80. Seo, H., Sunuoka, M., Hashimoto, T. Fujinaga, T., Otagiri, M. and Uekama, K. Enhancement of oral bioavailability of spironolactone by β- and γ-cyclodextrin complexations. Chem. Pharm. Bull. 1983; 31: 286–291.
81. Uekama, K. Pharmaceutical applications of methylated cyclodextrins. Pharm. Int. 1985; 6: 61–65.
82. Vila Jato, J.L., Blanco, J. and Vilar, A. Spironolactone/β-cyclodextrin complex: oral bioavailability in humans. Acta Pharm. Technol. 1986; 32: 82–85.
83. Koch-Weser, J. and Sellers, E.M. Binding of drugs to serum albumin. New Engl. J. Med. 1976; 294; 311–316.
84. Ng, A.S., Kluza, R.B. and Newton, D.W. Distribution coefficients and in vitro human serum protein binding of spironolactone and its 7α-carboxy-methyl analog. J. Pharm. Sci. 1980; 69: 30–32.
85. Huston, G.J. and Turner, P. Antagonism of fluorocortisone by spironolactone and canrenone. Br. J. Clin. Pharmacol. 1976; 3: 201–204.
86. Merkus, F.W.H.M. Is canrenone the major metabolite of spironolactone? Gin. Pharm. 1983; 2: 209–210.
87. Ramsay, L.E., Shelton, J.R., Wilkinson, D. and Tidd, M.J. Canrenone — the principal active metabolite of spironolactone? Br. J. Gin. Pharmacol. 1976; 3: 607–612.
88. Casals-Stenzel, J., Schmalbach, J. and Losert, W. Acute effects of aldosterone antagonists in volunteers. In: Addison, G.M., Wirenfeldt Asumussen, N., Corvol, P., et al, eds, Aldosterone antagonists in clinical medicine. Amsterdam-Oxford: Excerpta Medica, 1978; 207–216.
89. Mclnnes, G.T., Asbury, M.J., Shelton, J.R., Harrison, I.R., Ramsay, L.E., Venning, G.R. and Clarke, J.M. Activity of sulfur-containing intermediate metabolites of spironolactone. Clin. Pharmacol. Ther. 1980; 27: 363–369.
90. Ramsay, L.E. Clinical Pharmacology and therapeutic use of aldosterone antagonists. In: Agarwal, M.D., ed, Hormone antagonists. Berlin-New York: Walter de Gruyter and Co., 1982; 335–363.
91. Hofmann, L.M. Aldosterone antagonists in laboratory animals. In: Wesson, L.G. and Fanelli, G.M., eds, Recent advances in renal physiology and Pharmacology. Baltimore: University Press Park, 1974; 305–316.
92. Funder, J.W., Feldman, D., Highland, E. and Edelman, I.S. Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors. Biochem. Pharmacol. 1974; 23: 1493–1501.
93. Peterfalvi, M., Torelli, V., Foumex, R. and Rousseau, G. Importance of the lactonic ring in the activity of steroidal antialdosterones. Biochem. Pharmacol. 1980; 29: 353–357.
94. Sakauye, C. and Feldman, D. Agonist and anti-mineralocorticoid activities of spirolactones. Am. J. Physiol. 1976; 231: 93–97.
95. Mclnnes, G.J., Shelton, J.R., Ramsay, L.E., Harrison, I.R., Asbury, M.U., Clarke, J.M., Perkins, R.M. and Venning, G.R. Relative potency and structure activity relationships of aldosterone antagonists in healthy man: correlation with animal experience. Br. J. Clin. Pharmacol. 1982; 13: 331–339.
96. Funder, J.W., Mercer, J. and Hood, J. SC 23992: radioreceptor assays for therapeutic and side effects. Clin. Sci. Mol. Med. 1976; 51: 333S-3334S.
97. Rossier, B.C., Claire, M., Rafestin-Oblin, M.E., Geering, K., Gaggeler, H.P. and Corvol P. Binding and anti-mineralocorticoid activities of spirolactones in toad bladder. Am. J. Physiol. 1983; 244: C24-C31.
98. Sherry, J.H., O’Donnell, J.P. and Colby, H.D. Separation of spironolactone and its biologically active sulfur-containing metabolites by high-performance liquid chromatography. J. Chromatogr. 1986; 374: 183–190.
99. Ludbrook, A., Dynon, M., Mendelsohn, F.A.O. and Louis, WJ. Comparison of a single-dose and twice-a-day spironolactone therapy in mild hypertension. Med. J. Aust. 1980; 1: 124–125.
100. Caminos-Torres, R., Ma, L. and Snijder, PJ. Gynecomastia and semen abnormalities induced by spironolactone in normal men. J. Clin. Endocrinol. Metab. 1977; 45: 255–260.
101. Loriaux, D.L. Spironolactone and endocrine dysfunction. Ann. Intern. Med. 1976; 85: 630–636.
102. Huffman, D.H., Kampmann, J.P., Hignite, C.E. and Azanoff, D.L. Gynaecomastia induced in normal males by spironolactone. Clin. Pharmacol. Ther. 1978; 24: 465-473.
103. Levitt, J.J. Spironolactone therapy and amenorrhea. J.A.M.A. 1970; 211: 2014–2015.
104. Lobo, R.A., Shoupe, D., Serafini, P., Brinton, D. and Horton, R. The effects of two doses of spironolactone serum androgen and anagen hair in hirsute women. Fertil. Steril. 1985; 43: 200–205.
105. Cutler, G.B., Pita, J.C., Rifka, S.M., Menard, R.H., Sauer, M.A. and Loriaux, D.L. SC 25152: a potent mineralaocorticoid antagonist with reduced affinity for the 5α-dihydrotestosterone receptor of human and rat prostate. J. Clin. Endocrinol. Metab. 1978;47: 171–175.
106. Fernandez, M.D., Carter, G.D. and Palmer, T.N. The interaction of canrenone with oestrogen and progesterone receptors in human uterine cytosol. Br. J. Clin. Pharmacol. 1983; 15: 95–101.
107. Pita, J.C., Lippman, M.E., Thompson, E.B. and Loriaux, D.L. Interaction of spironolactone and digitalis with the 5α—dihydrotestosterone (DHT) receptor of rat ventral prostate. Endocrinology 1975; 97: 1521–1527.
108. Bellati, G. and Ideo, G. Gynaecomastia after spironolactone and potassium canrenoate. Lancet 1986; 1: 626.
109. Dupont, A. Disappearance of spironolactone-induced gynaecomastia during treatment with potassium canrenoate. Lancet 1985; 2: 731.
110. Fromantin, M. Surveillance clinique et hormonale des traitements prolonges de 1'hypertension arterielle par les anti-aldosterones. Mises Jour. Cardiol. 1980; 19: 95–98.
111. Armanini, D., Kartowiak, I., Goi, A., Mantero, F. and Funder, J.W. In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Clin. Endocrinol. 1985; 23: 341–347.
112. Anonymus. Kalium-Canrenoat- und Spironolacton-haltige Arzneimittel. Deutsche Apotheker Zeitung 1986; 126 (36): VII–VIII.
113. Anonymus. Kalium-Canrenoat- und Spironolacton-haltige Arzneimittel. Deutsche Apotheker Zeitung 1986; 126 (42): VIII–IX and 2312.
114. Anonymous. Spironolactone no longer to be used for treatment of hypertension. The Pharmaceutical Journal 1988; January 9: 57.
115. Hauswald, C.L., Cook, C.S., Koch, R.L. and Oppermann, J.A. In vitro metabolism of 14C-potassium canrenoate, 14C-spironolactone and 35S-spironolactone by rat liver microsomes. Pharmacologist 1986; 28: 212.